ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO1207

Dapagliflozin Ameliorates High-Fat, Diet-Induced, Megalin-Mediated Autolysosomal Disorders in Mouse Proximal Tubules

Session Information

  • CKD: Mechanisms - 2
    October 25, 2024 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

  • 2303 CKD (Non-Dialysis): Mechanisms

Authors

  • Takemoto, Kazuya, Niigata University, Niigata City, Niigata, Japan
  • Hosojima, Michihiro, Niigata University, Niigata City, Niigata, Japan
  • Kabasawa, Hideyuki, Niigata University, Niigata City, Niigata, Japan
  • Narita, Ichiei, Niigata University, Niigata City, Niigata, Japan
  • Saito, Akihiko, Niigata University, Niigata City, Niigata, Japan
Background

Megalin is a multi-ligand endocytic receptor located in the apical membrane of proximal tubules (PTs). Our prior study (JASN 2016) elucidated that megalin-mediated endocytosis of glomerular-filtered lipotoxic substances drives tubulo-glomerular alterations in mice fed a high-fat diet (HFD). In this model, pathological vacuolation appears particularly in segment 2 (S2) of PTs due to megalin-dependent autolysosomal disorders. Receptor-mediated endocytosis (RME) is the primary pathway for substance uptake in S1 (greater than S2), while fluid-phase endocytosis (FPE) prevails in S2, which is vulnerable to metabolic overload due to its less advanced endolysosomal systems. This investigation aims to explore the impact of dapagliflozin, an SGLT2 inhibitor, on autolysosomal disorders in PTs of HFD-fed mice and its underlying mechanism.

Methods

Nine-week-old male C57BL/6J mice were fed an HFD with oral administration of dapagliflozin (1mg/kg body weight/day) or vehicle for 28 days (n=10 each). Kidney sections underwent PAS staining, and Image-Pro Plus ver. 7.0 evaluated the vacuolar area/cortical tubular area. Urinary C-megalin, a marker for lysosomal overload in PTs (Diabetes 2017), was also measured. Renal megalin expression was gauged via immunoblotting, qPCR, and immunohistochemistry. Megalin's endocytic function was assessed by measuring the urinary excretion of α1-microglobulin, an endocytic ligand of megalin. RME and FPE were scrutinized on kidney sections post intravenous injection of fluorescent lysozyme and dextran, respectively, in 9-week-old male kidney-specific conditional megalin KO mice and littermate controls, and C57BL/6J mice receiving dapagliflozin or vehicle for 5 days.

Results

Dapagliflozin administration significantly reduced the vacuolar area/cortical tubular area and urinary C-megalin excretion in HFD-fed mice. While renal megalin expression remained unaltered, urinary α1-microglobulin excretion increased with dapagliflozin administration. In megalin KO mice, the uptake of fluorescent lysozyme and dextran in PTs decreased. Similarly, the administration of dapagliflozin to mice diminished the uptake of both tracers in PTs.

Conclusion

Dapagliflozin ameliorates HFD-induced, megalin-mediated autolysosomal disorders particularly in S2 of PTs by suppressing both RME and FPE dependent on megalin.

Funding

  • Commercial Support – Denka Company Limited